Trial-Results center  
Clinical trial results database Feedback    Home


Related trials

ZEST AMI (vs SES), 2009 - zotarolimus ES vs sirolimus ES

TRIANA, 2009 - primary ballon angioplasty vs tenecteplase

DEBATER (SES vs BMS), 2009 - sirolimus ES vs bare-metal stent

NORDISTEMI, 2009 - thrombolysis + angioplasty vs immediate thrombolysis

Juwana, 2009 - sirolimus ES vs paclitaxel ES

ZEST AMI (vs PES), 2009 - zotarolimus ES vs paclitaxel ES

PASEO, 2009 - drug ES vs bare-metal stent

CARESS, 2008 - thrombolysis + angioplasty vs immediate thrombolysis

HORIZONS-AMI Stent, 2008 - paclitaxel ES vs bare-metal stent

MISSION, 2008 - sirolimus ES vs bare-metal stent

DEDICATION, 2008 - drug ES vs bare-metal stent

Díaz de la Llera, 2007 - sirolimus ES vs bare-metal stent

SESAMI, 2007 - sirolimus ES vs bare-metal stent

TYPHOON, 2006 - sirolimus ES vs bare-metal stent

PROSIT, 2006 - sirolimus ES vs paclitaxel ES

HAAMU-STENT, 2006 - paclitaxel ES vs bare-metal stent

PASSION, 2006 - paclitaxel ES vs bare-metal stent

WEST, 2006 - systematic PCI (+stent) vs no systematic PCI

CAPITAL AMI, 2005 - thrombolysis + angioplasty vs immediate thrombolysis

Di Lorenzo et al., 2005 - sirolimus ES vs paclitaxel ES

ZWOLLE 6, 2005 - primary stenting vs ballon angioplasty

CAPITAL AMI, 2005 - systematic PCI (+stent) vs no systematic PCI

senior PAMI, 2005 - primary PCI vs thrombolytic therapy

STOPAMI 3, 2004 - primary stenting vs ballon angioplasty

GRACIA-1, 2004 - systematic PCI (+stent) vs no systematic PCI



See also:

  • All acute myocardial infarction clinical trials
  • All clinical trials of PCI
  • All clinical trials of primary stenting
    		•  

    PSSAAMI (Scheller) study, 2001

    Treatments

    Studied treatment Stent Wiktor GX
    Control treatment primary angioplasty
    Concomittant treatment Ticlopidine 500 mg/d for 4 weeks in stent group only, abciximab in 48% of patients in both groups
    Treatments description
    Crossover from Balloon Angioplasty to Stenting (%) 27  
    stent type Tensum III 

    Patients

    Patients patients within 24 hours after the onset of acute myocardial infarction
    Baseline characteristics
    Age 61y 
    male (%) 76% 

    Method and design

    Randomized effectives 44 / 44 (studied vs. control)
    Design Parallel groups
    Blinding open
    Follow-up duration 24 months


    Results

    Endpoint Studied treat.
    n/N     Control treat.
    n/N     Graph RR [95% CI]

    Long term death

    4 / 44
         8 / 44
         0,50 [0,16;1,54]

    reinfarction

    0 / 44
         1 / 44
         classic 0,20 [0,00;14,36]

    Revascularization

    0 / 44
         4 / 44
         classic 0,06 [0,00;3,25]

    Bleeding

    4 / 44
         6 / 44
         classic 0,67 [0,20;2,20]

    All cause death

    2 / 44
         1 / 44
         classic 2,00 [0,19;21,26]

    long term MI

    1 / 44
         4 / 44
         classic 0,25 [0,03;2,15]

    long term revascularization

    5 / 44
         17 / 44
         0,29 [0,12;0,73]     0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial    		 Ref
    Studied treat. Control treat.
    Long term death 4 / 44 (9,1%) 8 / 44 (18,2%) 0,50 [0,16;1,54]   7028 
    reinfarction 0 / 44 (1,1%) 1 / 44 (2,3%) 0,50 [0,02;14,52]   7028 
    Revascularization 0 / 44 (1,1%) 4 / 44 (9,1%) 0,13 [0,01;2,29]   7028 
    Bleeding 4 / 44 (9,1%) 6 / 44 (13,6%) 0,67 [0,20;2,20]   7028 
    All cause death 2 / 44 (4,5%) 1 / 44 (2,3%) 2,00 [0,19;21,26]   7028 
    long term MI 1 / 44 (2,3%) 4 / 44 (9,1%) 0,25 [0,03;2,15]   7028 
    long term revascularization 5 / 44 (11,4%) 17 / 44 (38,6%) 0,29 [0,12;0,73]   7028 
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:
  • 7028: Nordmann AJ, Bucher H, Hengstler P, Harr T, Young JPrimary stenting versus primary balloon angioplasty for treating acute myocardial infarction.Cochrane Database Syst Rev 2005;:CD005313
  • 0:

    • Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    Long term death 9,09% 18,18% -90,9‰
    Bleeding 9,09% 13,64% -45,5‰
    All cause death 4,55% 2,27% 2,3%
    long term MI 2,27% 9,09% -68,2‰
    long term revascularization 11,36% 38,64% -272,7‰


    Reference(s)

    Trials register # NA
    • Scheller B, Hennen B, Severin-Kneib S, Ozbek C, Schieffer H, Markwirth T. Long-term follow-up of a randomized study of primary stenting versus angioplasty in acute myocardial infarction.. Am J Med 2001;110:1-6
      Pubmed | Hubmed | Fulltext

    (c) 2004-2010 TrialResults-center - All Rights Reserved

    Tweet this  |  notify a friend